Major owner of Achillion Pharmaceuticals just picked up 2,369,229 shares

Capital Management, Ra, a major owner of Achillion Pharmaceuticals, recently acquired 2,369,229 shares of the company. The buys took place at prices ranging from $2.75 to $2.85 per share, on October 14, 2013. Ra now owns 145,193,792 shares of the company. Ra operates out of Boston, MA. Some additional info was provided as follows:

The securities purchased include 63,743 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 17,457 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account"). The securities purchased include 10,363 shares for the Fund and 2,837 shares for the Blackwell Account. The securities purchased include 373,424 shares for the Fund and 102,275 shares for the Blackwell Account. The securities purchased include 180,633 shares for the Fund and 49,467 shares for the Blackwell Account. The securities purchased include 745,752 shares for the Fund and 204,248 shares for the Blackwell Account. The securities purchased include 161,713 shares for the Fund and 44,287 shares for the Blackwell Account. The securities purchased include 290,373 shares for the Fund and 79,527 shares for the Blackwell Account. The securities purchased include 33,844 shares for the Fund and 9,286 shares for the Blackwell Account. Following the transactions set forth on Table I above, 14,899,145 shares are held by the Fund, and 4,375,855 shares are held in the Blackwell Account. RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Blackwell Account. Peter Kolchinsky is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interests therein. The filing of this Form 4 shall not be construed as an admission that Mr. Kolchinsky or the Adviser is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of securities reported herein.